Clinical trial · Interventional
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age. Growth failure, decline in cognitive function, and endocrine abnormalities have all been described. Good outcomes can be achieved with alkylating agents only as a preparative regimen. This plan will use a combination of busulfan and cyclophosphamide (Bu/Cy) with or without antithymocyte globulin (ATG) to reduce the late toxicities of therapy that includes TBI.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Leukemias | Acute Leukemia | ONTOLOGY_EXACT | 0.90 |
| Chronic Leukemias | Chronic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Juvenile Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Myelodysplastic Syndrome | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Busulfan/Cyclophosphamide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Busulfan/Cyclophosphamide
- interventionNames
- Drug: Busulfan/Cyclophosphamide
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- Five years
Secondary outcomes (1)
- measure
- Disease free survival
- timeFrame
- Five years
Eligibility
Eligibility (as posted)
- Sex
- Male
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Suitable cord blood from matched unrelated or related donor. * Cardiac (Echo/EKG): shortening fraction ≥ 27% * Electrolytes within normal CCHMC limits. * Pulmonary function tests: DLCO ≥ 50% * Renal: creatinine clearance/GFR ≥ 60 ml/minute/1.73m2 * Lumbar puncture: no leukemic infiltrate. * CBC: ANC ≥ 1000ml and unsupported platelet count of ≥ 50,000/ml * Documented HSV and CMV titers, Hepatitis B surface antigen, Hepatitis C by serology, HIV by serology: all negative. * Hepatic transaminases \< 2.5x normal; Total bilirubin \< 2 mg/dl Patients who do not meet above organ function criteria (liver, cardiac, renal), due to the presence of a tumor compromising these organs, may have exception made for these criteria and remain eligible for treatment plan after consultation with Program Director of Blood and Marrow Transplant Exclusion Criteria: * Patients with neoplastic or non-neoplastic disease of any major organ system that would compromise their ability to withstand the pre-transplant conditioning regimen. * Patients with uncontrolled (culture or biopsy positive) infections requiring intravenous antivirals, antibiotics, or antifungals. Patients on prolonged antifungal therapy with a history of fungal infection should be considered for a non-myeloablative protocol. * Patients who are pregnant or lactating. Patients of childbearing potential must practice an effective method of birth control while participating on this treatment plan. * HIV seropositive patients
References
Publications (0)
Data not yet available